BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Stoklosa, T., Poplawski, T., Koptyra, M., Nieborowska-Skorska, M., Basak, G., Slupianek, A., Rayevskaya, M., Seferynska, I., Herrera, L., Blasiak, J., & Skorski, T. Cancer Research, 68(8):2576–2580, April, 2008. WOS:000255100500006doi abstract bibtex BCR/ABL kinase-positive chronic myelogenous leukemia (CML) cells display genomic instability leading to point mutations in various genes including bcr/abl and p53, eventually causing resistance to imatinib and malignant progression of the disease. Mismatch repair (MMR) is responsible for detecting misincorporated nucleotides, resulting in excision repair before point mutations occur and/or induction of apoptosis to avoid propagation of cells carrying excessive DNA lesions. To assess MMR activity in CML,,we used an in vivo assay using the plasmid substrate containing enhanced green fluorescent protein (EGFP) gene corrupted by T:G mismatch in the start codon; therefore, MMR restores EGFP expression. The efficacy of MMR was reduced similar to 2-fold in BCR/ABL-positive cell lines and CD34(+) CML cells compared with normal counterparts. MMR was also challenged by N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), which generates O-6-methylguanine and O-4-methylthymine recognized by MMR system. Impaired MMR activity in leukemia cells was associated with better survival, accumulation of p53 but not of p73, and lack of activation of caspase 3 after MNNG treatment. In contrast, parental cells displayed accumulation of p53, p73, and activation of caspase 3, resulting in cell death. Ouabain-resistance test detecting mutations in the Na+/K+ ATPase was used to investigate the effect of BCR/ABL kinase-mediated inhibition of MMR on mutagenesis. BCR/ABL-positive cells surviving the treatment with MNNG displayed similar to 15-fold higher mutation frequency than parental counterparts and predominantly G:C -\textgreater A:T and A:T -\textgreater G:C mutator phenotype typical for MNNG-induced unrepaired lesions. In conclusion, these results suggest that BCR/ABL kinase abrogates MMR activity to inhibit apoptosis and induce mutator phenotype.
@article{stoklosa_bcrabl_2008,
title = {{BCR}/{ABL} inhibits mismatch repair to protect from apoptosis and induce point mutations},
volume = {68},
issn = {0008-5472},
doi = {10.1158/0008-5472.CAN-07-6858},
abstract = {BCR/ABL kinase-positive chronic myelogenous leukemia (CML) cells display genomic instability leading to point mutations in various genes including bcr/abl and p53, eventually causing resistance to imatinib and malignant progression of the disease. Mismatch repair (MMR) is responsible for detecting misincorporated nucleotides, resulting in excision repair before point mutations occur and/or induction of apoptosis to avoid propagation of cells carrying excessive DNA lesions. To assess MMR activity in CML,,we used an in vivo assay using the plasmid substrate containing enhanced green fluorescent protein (EGFP) gene corrupted by T:G mismatch in the start codon; therefore, MMR restores EGFP expression. The efficacy of MMR was reduced similar to 2-fold in BCR/ABL-positive cell lines and CD34(+) CML cells compared with normal counterparts. MMR was also challenged by N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), which generates O-6-methylguanine and O-4-methylthymine recognized by MMR system. Impaired MMR activity in leukemia cells was associated with better survival, accumulation of p53 but not of p73, and lack of activation of caspase 3 after MNNG treatment. In contrast, parental cells displayed accumulation of p53, p73, and activation of caspase 3, resulting in cell death. Ouabain-resistance test detecting mutations in the Na+/K+ ATPase was used to investigate the effect of BCR/ABL kinase-mediated inhibition of MMR on mutagenesis. BCR/ABL-positive cells surviving the treatment with MNNG displayed similar to 15-fold higher mutation frequency than parental counterparts and predominantly G:C -{\textgreater} A:T and A:T -{\textgreater} G:C mutator phenotype typical for MNNG-induced unrepaired lesions. In conclusion, these results suggest that BCR/ABL kinase abrogates MMR activity to inhibit apoptosis and induce mutator phenotype.},
language = {English},
number = {8},
journal = {Cancer Research},
author = {Stoklosa, Tomasz and Poplawski, Tomasz and Koptyra, Mateusz and Nieborowska-Skorska, Margaret and Basak, Grzegorz and Slupianek, Artur and Rayevskaya, Marina and Seferynska, Ilona and Herrera, Larry and Blasiak, Janusz and Skorski, Tomasz},
month = apr,
year = {2008},
note = {WOS:000255100500006},
keywords = {Animals, Apoptosis, Base Pair Mismatch, Cell Line, Transformed, DNA Repair, Disease Progression, Drug Resistance, Neoplasm, Fusion Proteins, bcr-abl, Genes, Reporter, Genomic Instability, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mice, Mutagenesis, Point Mutation, Sodium-Potassium-Exchanging ATPase, bcr-abl, bcr/abl, cell-lines, chronic myeloid-leukemia, evolution, gene, imatinib, mismatch repair, p53, resistance},
pages = {2576--2580},
}
Downloads: 0
{"_id":"9w5yQPTzEDq4nNaWz","bibbaseid":"stoklosa-poplawski-koptyra-nieborowskaskorska-basak-slupianek-rayevskaya-seferynska-etal-bcrablinhibitsmismatchrepairtoprotectfromapoptosisandinducepointmutations-2008","downloads":0,"creationDate":"2016-01-18T20:52:08.575Z","title":"BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations","author_short":["Stoklosa, T.","Poplawski, T.","Koptyra, M.","Nieborowska-Skorska, M.","Basak, G.","Slupianek, A.","Rayevskaya, M.","Seferynska, I.","Herrera, L.","Blasiak, J.","Skorski, T."],"year":2008,"bibtype":"article","biburl":"https://api.zotero.org/users/2155425/collections/TKJNHEUE/items?key=63tuNzMcoax0HUKkTKgzxktn&format=bibtex&limit=100","bibdata":{"bibtype":"article","type":"article","title":"BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations","volume":"68","issn":"0008-5472","doi":"10.1158/0008-5472.CAN-07-6858","abstract":"BCR/ABL kinase-positive chronic myelogenous leukemia (CML) cells display genomic instability leading to point mutations in various genes including bcr/abl and p53, eventually causing resistance to imatinib and malignant progression of the disease. Mismatch repair (MMR) is responsible for detecting misincorporated nucleotides, resulting in excision repair before point mutations occur and/or induction of apoptosis to avoid propagation of cells carrying excessive DNA lesions. To assess MMR activity in CML,,we used an in vivo assay using the plasmid substrate containing enhanced green fluorescent protein (EGFP) gene corrupted by T:G mismatch in the start codon; therefore, MMR restores EGFP expression. The efficacy of MMR was reduced similar to 2-fold in BCR/ABL-positive cell lines and CD34(+) CML cells compared with normal counterparts. MMR was also challenged by N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), which generates O-6-methylguanine and O-4-methylthymine recognized by MMR system. Impaired MMR activity in leukemia cells was associated with better survival, accumulation of p53 but not of p73, and lack of activation of caspase 3 after MNNG treatment. In contrast, parental cells displayed accumulation of p53, p73, and activation of caspase 3, resulting in cell death. Ouabain-resistance test detecting mutations in the Na+/K+ ATPase was used to investigate the effect of BCR/ABL kinase-mediated inhibition of MMR on mutagenesis. BCR/ABL-positive cells surviving the treatment with MNNG displayed similar to 15-fold higher mutation frequency than parental counterparts and predominantly G:C -\\textgreater A:T and A:T -\\textgreater G:C mutator phenotype typical for MNNG-induced unrepaired lesions. In conclusion, these results suggest that BCR/ABL kinase abrogates MMR activity to inhibit apoptosis and induce mutator phenotype.","language":"English","number":"8","journal":"Cancer Research","author":[{"propositions":[],"lastnames":["Stoklosa"],"firstnames":["Tomasz"],"suffixes":[]},{"propositions":[],"lastnames":["Poplawski"],"firstnames":["Tomasz"],"suffixes":[]},{"propositions":[],"lastnames":["Koptyra"],"firstnames":["Mateusz"],"suffixes":[]},{"propositions":[],"lastnames":["Nieborowska-Skorska"],"firstnames":["Margaret"],"suffixes":[]},{"propositions":[],"lastnames":["Basak"],"firstnames":["Grzegorz"],"suffixes":[]},{"propositions":[],"lastnames":["Slupianek"],"firstnames":["Artur"],"suffixes":[]},{"propositions":[],"lastnames":["Rayevskaya"],"firstnames":["Marina"],"suffixes":[]},{"propositions":[],"lastnames":["Seferynska"],"firstnames":["Ilona"],"suffixes":[]},{"propositions":[],"lastnames":["Herrera"],"firstnames":["Larry"],"suffixes":[]},{"propositions":[],"lastnames":["Blasiak"],"firstnames":["Janusz"],"suffixes":[]},{"propositions":[],"lastnames":["Skorski"],"firstnames":["Tomasz"],"suffixes":[]}],"month":"April","year":"2008","note":"WOS:000255100500006","keywords":"Animals, Apoptosis, Base Pair Mismatch, Cell Line, Transformed, DNA Repair, Disease Progression, Drug Resistance, Neoplasm, Fusion Proteins, bcr-abl, Genes, Reporter, Genomic Instability, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mice, Mutagenesis, Point Mutation, Sodium-Potassium-Exchanging ATPase, bcr-abl, bcr/abl, cell-lines, chronic myeloid-leukemia, evolution, gene, imatinib, mismatch repair, p53, resistance","pages":"2576–2580","bibtex":"@article{stoklosa_bcrabl_2008,\n\ttitle = {{BCR}/{ABL} inhibits mismatch repair to protect from apoptosis and induce point mutations},\n\tvolume = {68},\n\tissn = {0008-5472},\n\tdoi = {10.1158/0008-5472.CAN-07-6858},\n\tabstract = {BCR/ABL kinase-positive chronic myelogenous leukemia (CML) cells display genomic instability leading to point mutations in various genes including bcr/abl and p53, eventually causing resistance to imatinib and malignant progression of the disease. Mismatch repair (MMR) is responsible for detecting misincorporated nucleotides, resulting in excision repair before point mutations occur and/or induction of apoptosis to avoid propagation of cells carrying excessive DNA lesions. To assess MMR activity in CML,,we used an in vivo assay using the plasmid substrate containing enhanced green fluorescent protein (EGFP) gene corrupted by T:G mismatch in the start codon; therefore, MMR restores EGFP expression. The efficacy of MMR was reduced similar to 2-fold in BCR/ABL-positive cell lines and CD34(+) CML cells compared with normal counterparts. MMR was also challenged by N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), which generates O-6-methylguanine and O-4-methylthymine recognized by MMR system. Impaired MMR activity in leukemia cells was associated with better survival, accumulation of p53 but not of p73, and lack of activation of caspase 3 after MNNG treatment. In contrast, parental cells displayed accumulation of p53, p73, and activation of caspase 3, resulting in cell death. Ouabain-resistance test detecting mutations in the Na+/K+ ATPase was used to investigate the effect of BCR/ABL kinase-mediated inhibition of MMR on mutagenesis. BCR/ABL-positive cells surviving the treatment with MNNG displayed similar to 15-fold higher mutation frequency than parental counterparts and predominantly G:C -{\\textgreater} A:T and A:T -{\\textgreater} G:C mutator phenotype typical for MNNG-induced unrepaired lesions. In conclusion, these results suggest that BCR/ABL kinase abrogates MMR activity to inhibit apoptosis and induce mutator phenotype.},\n\tlanguage = {English},\n\tnumber = {8},\n\tjournal = {Cancer Research},\n\tauthor = {Stoklosa, Tomasz and Poplawski, Tomasz and Koptyra, Mateusz and Nieborowska-Skorska, Margaret and Basak, Grzegorz and Slupianek, Artur and Rayevskaya, Marina and Seferynska, Ilona and Herrera, Larry and Blasiak, Janusz and Skorski, Tomasz},\n\tmonth = apr,\n\tyear = {2008},\n\tnote = {WOS:000255100500006},\n\tkeywords = {Animals, Apoptosis, Base Pair Mismatch, Cell Line, Transformed, DNA Repair, Disease Progression, Drug Resistance, Neoplasm, Fusion Proteins, bcr-abl, Genes, Reporter, Genomic Instability, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mice, Mutagenesis, Point Mutation, Sodium-Potassium-Exchanging ATPase, bcr-abl, bcr/abl, cell-lines, chronic myeloid-leukemia, evolution, gene, imatinib, mismatch repair, p53, resistance},\n\tpages = {2576--2580},\n}\n\n","author_short":["Stoklosa, T.","Poplawski, T.","Koptyra, M.","Nieborowska-Skorska, M.","Basak, G.","Slupianek, A.","Rayevskaya, M.","Seferynska, I.","Herrera, L.","Blasiak, J.","Skorski, T."],"key":"stoklosa_bcrabl_2008","id":"stoklosa_bcrabl_2008","bibbaseid":"stoklosa-poplawski-koptyra-nieborowskaskorska-basak-slupianek-rayevskaya-seferynska-etal-bcrablinhibitsmismatchrepairtoprotectfromapoptosisandinducepointmutations-2008","role":"author","urls":{},"keyword":["Animals","Apoptosis","Base Pair Mismatch","Cell Line","Transformed","DNA Repair","Disease Progression","Drug Resistance","Neoplasm","Fusion Proteins","bcr-abl","Genes","Reporter","Genomic Instability","Humans","Leukemia","Myelogenous","Chronic","BCR-ABL Positive","Mice","Mutagenesis","Point Mutation","Sodium-Potassium-Exchanging ATPase","bcr-abl","bcr/abl","cell-lines","chronic myeloid-leukemia","evolution","gene","imatinib","mismatch repair","p53","resistance"],"metadata":{"authorlinks":{}}},"search_terms":["bcr","abl","inhibits","mismatch","repair","protect","apoptosis","induce","point","mutations","stoklosa","poplawski","koptyra","nieborowska-skorska","basak","slupianek","rayevskaya","seferynska","herrera","blasiak","skorski"],"keywords":["animals","apoptosis","base pair mismatch","cell line","transformed","dna repair","disease progression","drug resistance","neoplasm","fusion proteins","bcr-abl","genes","reporter","genomic instability","humans","leukemia","myelogenous","chronic","bcr-abl positive","mice","mutagenesis","point mutation","sodium-potassium-exchanging atpase","bcr-abl","bcr/abl","cell-lines","chronic myeloid-leukemia","evolution","gene","imatinib","mismatch repair","p53","resistance"],"authorIDs":[],"dataSources":["gf7ufzFmBPGzLgCG4","viLGND2MCKuo7H8vL","YLgywGcXWx96vKKaB","4ZWTcT5tTetPkGKTK"]}